TenNor Therapeutics team attended ASM Microbe 2016 Conference held in Boston USA and presented TNP-2092 for Helicobacter pylori infection (HPI) program in public the first time.

TenNor submitted a series of 7 poster abstracts around dual-acting molecule TNP-2092 for HPI program and all were accepted for presentation at the conference. TenNor was also selected by the ASM Program Committee to present TNP-2092 program in a “New Antimicrobial Agents” session. On behalf of TenNor Therapeutics, Dr. Zhenkun Ma, Founder and CEO, provided an overview of the TNP-2092 HPI program to a general audience.

TenNor’s collaborators William Weiss, Mark Pulse (both from UNT Health Science Center) and Gregory Robertson (Colorado State University), together with TenNor’s team members Xiaomei Wang and Xiangyi Xu participated in the poster presentations.

Link to TenNor posters：

Annex:

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com